Cargando…

Gastrointestinal Bleeding Secondary to High-Dose Melphalan Pretreatment in Patients with Multiple Myeloma Was Associated with the Mode of Melphalan Administration

OBJECTIVE: To analyze the characteristics of gastrointestinal bleeding secondary to high-dose melphalan pretreatment in patients with multiple myeloma. METHODS: Between 1 January 2016 and 31 October 2021, 26 patients with multiple myeloma after autologous peripheral blood hematopoietic stem cell tra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ge, Qunfang, Wang, Yi, Zhu, Huiling, Xu, Kaihong, Sheng, Lixia, Yan, Xiaoyan, Ouyang, Guifang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293567/ https://www.ncbi.nlm.nih.gov/pubmed/35860001 http://dx.doi.org/10.1155/2022/2088217

Ejemplares similares

Retracted: Gastrointestinal Bleeding Secondary to High-Dose Melphalan Pretreatment in Patients with Multiple Myeloma Was Associated with the Mode of Melphalan Administration
por: and Alternative Medicine, Evidence-Based Complementary
Publicado: (2023)

Repeat administration of high dose melphalan in relapsed myeloma.
por: Mansi, J. L., et al.
Publicado: (1993)

Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment
por: Lee, Se Ryeon, et al.
Publicado: (2019)

Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
por: Rodriguez, Tulio E., et al.
Publicado: (2016)

Busulfan plus melphalan versus high-dose melphalan as conditioning regimens in autologous stem cell transplantation for newly diagnosed multiple myeloma
por: Byun, Ja Min, et al.
Publicado: (2018)

The Combination of Panobinostat and Melphalan for the Treatment of Patients with Multiple Myeloma
por: Gkotzamanidou, Maria, et al.
Publicado: (2022)

Effect of high-dose melphalan on marrow and intestinal epithelium in mice pretreated with cyclophosphamide.
por: Millar, J. L., et al.
Publicado: (1978)

Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma
por: Srour, Samer A., et al.
Publicado: (2021)

Efficacy and Safety of High-Dose Chemotherapy with Treosulfan and Melphalan in Multiple Myeloma
por: Gillich, Cédric, et al.
Publicado: (2023)

Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma
por: Morabito, Fortunato, et al.
Publicado: (2021)

Adding bendamustine to melphalan before ASCT improves CR rate in myeloma vs. melphalan alone: A randomized phase-2 trial
por: Farag, Sarah, et al.
Publicado: (2022)

Antioxidant Defenses Confer Resistance to High Dose Melphalan in Multiple Myeloma Cells
por: Gourzones, Claire, et al.
Publicado: (2019)

Phase 2 Clinical Trial of High-Dose Gemcitabine/Busulfan/Melphalan for Autologous Stem-Cell Transplantation in Relapsed/Refractory Myeloma: Matched-Pair Comparison with Melphalan
por: Nieto, Yago, et al.
Publicado: (2017)

Decreased melphalan accumulation in a human breast cancer cell line selected for resistance to melphalan.
por: Moscow, J. A., et al.
Publicado: (1993)

Busulfan plus melphalan versus melphalan alone conditioning regimen after bortezomib based triplet induction chemotherapy for patients with newly diagnosed multiple myeloma
por: Park, Songyi, et al.
Publicado: (2021)

Functional analysis of the involvement of apurinic/apyrimidinic endonuclease 1 in the resistance to melphalan in multiple myeloma
por: Xie, Jiayin, et al.
Publicado: (2014)

Factors influencing the chemosensitization of melphalan by misonidazole.
por: Randhawa, V. S., et al.
Publicado: (1985)

Influence of PJ34 on the genotoxicity induced by melphalan in human multiple myeloma cells
por: Xiong, Ting, et al.
Publicado: (2015)

TAK1-inhibitors are cytotoxic for multiple myeloma cells alone and in combination with melphalan
por: Håland, Erling, et al.
Publicado: (2021)

Challenges associated with test dose pharmacokinetic predictions of high dose melphalan exposure in patients with multiple myeloma
por: Nath, Christa Ellen, et al.
Publicado: (2022)

Bortezomib and melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma
por: Lee, Se Ryeon, et al.
Publicado: (2010)

Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study
por: Hjorth, Martin, et al.
Publicado: (2012)

Cytotoxic efficacy of filanesib and melphalan combination is governed by sequence of treatment in human myeloma cells
por: Norris, E J, et al.
Publicado: (2016)

Decitabine and Melphalan Fail to Reactivate p73 in p53 Deficient Myeloma Cells
por: Gillardin, Pierre-Samuel, et al.
Publicado: (2017)

Comparison of two melphalan protocols and evaluation of outcome and prognostic factors in multiple myeloma in dogs
por: Fernández, Ricardo, et al.
Publicado: (2018)

Cost-Effectiveness Analysis of Adding Daratumumab to Bortezomib, Melphalan, and Prednisone for Untreated Multiple Myeloma
por: Cao, Yaohua, et al.
Publicado: (2021)

Bortezomib in combination with low-dose oral melphalan, dexamethasone and thalidomide for relapsed elderly patients with multiple myeloma
por: Azarm, Taleb, et al.
Publicado: (2012)

Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age
por: Mai, Elias K., et al.
Publicado: (2020)

The effect of systemic hyperthermia on melphalan pharmacokinetics in mice.
por: Honess, D. J., et al.
Publicado: (1985)

The effect of radiosensitizers on the pharmacokinetics of melphalan and cyclophosphamide in the mouse.
por: Hinchliffe, M., et al.
Publicado: (1983)

Oral Melphalan Therapy in Advanced Malignant Disease
por: Clifford, Peter, et al.
Publicado: (1963)

Nitric oxide enhancement of melphalan-induced cytotoxicity.
por: Cook, J. A., et al.
Publicado: (1997)

Intravitreal and Subconjunctival Melphalan for Retinoblastoma in Transgenic Mice
por: Shah, Nisha V., et al.
Publicado: (2014)

Intravitreal Melphalan Chemotherapy for Vitreous Seeds in Retinoblastoma
por: Yousef, Yacoub A., et al.
Publicado: (2020)

Intravitreal melphalan for persistent retinoblastoma vitreous seeds
por: Redondo-Villanueva, Marie Jeazelle H., et al.
Publicado: (2022)

Toxicity to intravitreal melphalan in a patient with retinoblastoma
por: Solaz-Ruiz, Marta Gema, et al.
Publicado: (2023)

High-dose melphalan with autologous marrow for treatment of advanced neuroblastoma.
por: Pritchard, J., et al.
Publicado: (1982)

Effect of misonidazole or metronidazole pretreatment on the response of the RIF-1 mouse sarcoma to melphalan, cyclophosphamide, chlorambucil and CCNU.
por: Twentyman, P., et al.
Publicado: (1982)

A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients.
por: Belch, A., et al.
Publicado: (1988)

Treatment of Multiple Myeloma and the Role of Melphalan in the Era of Modern Therapies—Current Research and Clinical Approaches
por: Poczta, Anastazja, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_flmpkl385pc6v20abtivbbmok0